Iaso Ventures
VC Fund
Boston, United States
Iaso Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Iaso Ventures is the nation's first venture capital firm focusing on the behavioral and neurological health sector.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Iaso Ventures invests in
Stages Iaso Ventures invests in
Countries Iaso Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 7 (41%)
- Health Care 5 (29%)
- Artificial Intelligence 3 (18%)
- Software 2 (12%)
- Life Science 2 (12%)
Stage
- Series A 8 (47%)
- Seed 5 (29%)
- Pre-Seed 1 (6%)
- Funding Round 1 (6%)
- Venture - Series Unknown 1 (6%)
Country
- United States 11 (65%)
- Norway 1 (6%)
- Ireland 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Reynders
Venture Partner and Chief Data Scientist
|
Venture Partner and Chief Data Scientist | Total investments: 0 | Find email | |
Wasim Malik
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
William Morrison
Venture Partner
|
Venture Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders. | $39M / Series A / Feb 09, 2026 | ||
| Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $20M / Series A / Jan 07, 2026 | ||
| Synthetica Bio develops an enterprise-scale generative AI for biopharma. It empowers discovery, clinical, and commercial teams with actionable knowledge in real-time. Its platform fine-tunes LLMs for real-time data with the verified and secure customer data store. | $3M / Seed / Jun 12, 2025 | ||
| Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $7M / Seed / Jan 09, 2025 | ||
| Axonis translates breakthrough regeneration research to groundbreaking paralysis therapy, to transform the lives of spinal cord injury patients. | $115M / Series A / Oct 30, 2024 | ||
| A venture backed, tech-accelerated drug development company. | Seed / Jan 01, 2024 | ||
| Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States. | $23M / Series A / Dec 11, 2023 | ||
| Synthetica Bio develops an enterprise-scale generative AI for biopharma. It empowers discovery, clinical, and commercial teams with actionable knowledge in real-time. Its platform fine-tunes LLMs for real-time data with the verified and secure customer data store. | $2.5M / Seed / Nov 01, 2023 | ||
| VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease.The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate publicand private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes.It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018. | $10M / Series A / Mar 22, 2023 | ||
| ClexBio is a pre-clinical stage regenerative medicine company that has developed a ground-breaking proprietary technology platform for scalable, high-throughput tissue generation. ClexBio holds patents for a highly innovative method for producing biocompatible hydrogels, as well as the technology for growing large tissues from healthy human cellsin complex geometric shapes. | Venture - Series Unknown / Jan 01, 2023 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Iaso Ventures invest in?
Iaso Ventures invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Iaso Ventures?
Public channels for Iaso Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Iaso Ventures?
The team at Iaso Ventures includes John Reynders (Venture Partner and Chief Data Scientist), Wasim Malik (Managing Partner) and William Morrison (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
